Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
US Army
AstraZeneca
Citi
Farmers Insurance
Daiichi Sankyo
Healthtrust
Merck
Federal Trade Commission
Johnson and Johnson

Generated: January 22, 2018

DrugPatentWatch Database Preview

Claims for Patent: 6,936,590

« Back to Dashboard

Summary for Patent: 6,936,590
Title: C-aryl glucoside SGLT2 inhibitors and method
Abstract:A method is provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of a compound of the formula ##STR1## alone or in combination with one or more other antidiabetic agent(s) or other therapeutic agent(s).
Inventor(s): Washburn; William N. (Titusville, NJ), Ellsworth; Bruce (Princeton, NJ), Meng; Wei (Pennington, NJ), Wu; Gang (Princeton, NJ), Sher; Philip M. (Plainsboro, NJ)
Assignee: Bristol Myers Squibb Company (Princeton, NJ)
Application Number:10/264,410
Patent Claims: 1. A method for treating diabetes, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, insulin resistance, hyperglycemia, hyperinsulinemia, hyperlipidemia, obesity, hypertriglyceridemia or atherosclerosis via the inhibition of SGLT2 transporters which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound of formula I having the structure ##STR116##

wherein R.sup.1, R.sup.2 and R.sup.2a are independently selected from the group consisting of hydrogen, OH, OR.sup.5, alkyl, CF.sub.3, OCHF.sub.2, OCF.sub.3, SR.sup.5i or halogen, or two of R.sup.1, R.sup.2 and R.sup.2a together with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO.sub.2 ; R.sup.1 and R.sup.4 are each independently selected from the group consisting of hydrogen, OH, OR.sup.5a,OAryl, OCH.sub.2 Aryl, alkyl, cycloalkyl, CF.sub.3, --OCHF.sub.2, --OCF.sub.3, halogen, --CN, --CO.sub.2 R.sup.5b, --CO.sub.2 H, COR.sup.6b, --CH(OH)R.sup.6c, --CH(OR.sup.5h)R.sup.6d, --CONR.sup.6 R.sup.6a, --NHCOR.sup.5c, --NHSO.sub.2 R.sup.5d, --NHSO.sub.2 Aryl, Aryl, --SR.sup.5e, --SOR.sup.5f, --SO.sub.2 R.sup.5g, --SO.sub.2 Aryl, and a five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO.sub.2, or R.sup.3 and R.sup.4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO.sub.2 ; R.sup.5, R.sup.5a, R.sup.5b, R.sup.5c, R.sup.5d, R.sup.5e, R.sup.5f, R.sup.5g, R.sup.5h and R.sup.5i are independently alkyl; R.sup.6, R.sup.6a, R.sup.6b, R.sup.6c, and R.sup.6d are are each independently selected from the group consisting of hydrogen, alkyl, aryl, alkylaryl and cycloalkyl, or R.sup.6 and R.sub.5a together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO.sub.2 ; and A is O or (CH.sub.2).sub.n where n is 0-3, or a pharmaceutically acceptable salt, stereoisomer, or prodrug ester thereof.

2. The method as defined in claim 1 comprising administering a therapeutically effective amount of a compound of formula I having the structure ##STR117##

3. A method for treating diabetes, via the inhibition of SGLT2 transporters which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compound of formula I having the structure ##STR118##

wherein R.sup.1, R.sup.2 and R.sup.2a are independently selected from the group consisting of hydrogen, OH, OR.sup.5, alkyl, CF.sub.3, OCHF.sub.2, OCF.sub.3, SR.sup.5i and halogen, or two of R.sup.1, R.sup.2 and R.sup.2a together with the carbons to which they are attached can form an annelated five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO.sub.2 ; R.sup.3 and R.sup.4 are each independently selected from the group consisting of hydrogen, OH, OR.sup.5a, OAryl, OCH.sub.2 Aryl, alkyl, cycloalkyl, CF.sub.3, --OCHF.sub.2, --OCF.sub.3, halogen, --CN, --CO.sub.2 R.sup.5b, --CO.sub.2 H, COR.sup.6b, --CH(OH)R.sup.6c, --CH(OR.sup.5h)R.sup.6d, --CONR.sup.6 R.sup.6a, --NHCOR.sup.5c, --NHSO.sub.2 R.sup.5d, --NHSO.sub.2 Aryl, Aryl, --SR.sup.5e, --SOR.sup.5f, --SO.sub.2 R.sup.5g, --SO.sub.2 Aryl, and a five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO.sub.2, or R.sup.3 and R.sup.4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO.sub.2 ; R.sup.5, R.sup.5a, R.sup.5b, R.sup.5c, R.sup.5d, R.sup.5e, R.sup.5f, R.sup.5g, R.sup.5h and R.sup.5i are independently alkyl; R.sup.6, R.sup.6a, R.sup.6b, R.sup.6c, and R.sup.6d are each independently selected from the group consisting of hydrogen, alkyl, aryl, alkylaryl and cycloalkyl, or R.sup.6 and R.sub.5a together with the nitrogen to which they are attached form an annelated five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring which are N, O, S, SO, and/or SO.sub.2 ; and A is O or (CH.sub.2).sub.n where n is 0-3, or a pharmaceutically acceptable salt, stereoisomer, or prodrug ester thereof.

4. The method as defined in claim 1 comprising administering a therapeutically effective amount of a compound of formula I and at least one antidiabetic agent selected from the group consisting of metformin, glyburide, glimepiride, glipyride, glipizide, chlorpropamide, gliclazide, acarbose, miglitol, pioglitazone, troglitazone, rosiglitazone, insulin, isaglitazone, repaglinide and nateglinide.

5. The method as defined in claim 1 comprising administering a therapeutically effective amount of a compound of formula I and at least one anti-obesity agent selected from the group consisting of orlistat, sibutramine, topiramate, axokine, dexamphetamine, phentermine, phenylpropanolamine and mazindol.

6. The method as defined in claim 1 comprising administering a therapeutically effective amount of a compound of formula I and at least one lipid lowering agent selected from the group consisting of pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, nisvastatin, visastatin, atavastatin, rosuvastatin, fenofibrate, gemfibrozil, clofibrate and avasimibe.

7. The method as defined in claim 3 comprising administering a therapeutically effective amount of a compound of formula I and at least one antidiabetic agent selected from the group consisting of metformin, glyburide, glimepiride, glipyride, glipizide, chlorpropamide, gliclazide, acarbose, maglitol, pioglitazone, troglitazone, rosiglitazone, insulin, isaglitazone, repaglinide and nateglinide.

8. The method as defined in claim 3 comprising administering a therapeutically effective amount of a compound of formula I and at least one anti-obesity agent selected from the group consisting of orlistat, sibutramine, topiramate, axokine, dexamphetamine, phentermine, phenylpropanolamine and mazindol.

9. The method as defined in claim 3 comprising administering a therapeutically effective amount of a compound of formula I and at least one lipid lowering agent selected from the group consisting of pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, nisvastatin, visastatin, atavastatin, rosuvastatin, fenofibrate, gemfibrozil, clofibrate and avasimibe.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Mallinckrodt
Healthtrust
Novartis
Chubb
Citi
Cipla
Cantor Fitzgerald
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot